Cargando…

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer

Breast cancer is the second most common cause of cancer-related deaths worldwide among women. Despite several therapeutic options, 15% of breast cancer patients succumb to the disease owing to tumor relapse and acquired therapy resistance. Particularly in triple-negative breast cancer (TNBC), develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iskit, Sedef, Lieftink, Cor, Halonen, Pasi, Shahrabi, Aida, Possik, Patricia A., Beijersbergen, Roderick L., Peeper, Daniel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189992/ https://www.ncbi.nlm.nih.gov/pubmed/27374095 http://dx.doi.org/10.18632/oncotarget.10230

Ejemplares similares

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival
por: Iskit, Sedef, et al.
Publicado: (2015)

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities
por: Lieftink, Cor, et al.
Publicado: (2021)

Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling
por: Brunen, Diede, et al.
Publicado: (2016)

Identification of signalling cascades involved in red blood cell shrinkage and vesiculation
por: Kostova, Elena B., et al.
Publicado: (2015)

The epidermal growth factor receptor (EGRF) in lung cancer
por: Carcereny, Enric, et al.
Publicado: (2015)

Cripto-1 as a novel therapeutic target for triple negative breast cancer
por: Castro, Nadia P., et al.
Publicado: (2014)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
por: Kozin, Sergey V., et al.
Publicado: (2017)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Na(+)/H(+) exchanger NHE1 regulation modulates metastatic potential and epithelial-mesenchymal transition of triple-negative breast cancer cells
por: Amith, Schammim Ray, et al.
Publicado: (2016)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
por: Hasegawa, Masanori, et al.
Publicado: (2016)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers
por: Gasparini, Pierluigi, et al.
Publicado: (2014)

Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer
por: Bansal, Nidhi, et al.
Publicado: (2015)

Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D context
por: Matsubara, Masahiro, et al.
Publicado: (2016)

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
por: Smit, Marjon A, et al.
Publicado: (2014)

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
por: Gallenne, Tristan, et al.
Publicado: (2017)

Senescent stromal cells induce cancer cell migration via inhibition of RhoA/ROCK/myosin-based cell contractility
por: Aifuwa, Ivie, et al.
Publicado: (2015)

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen
por: Schepers, Arnout, et al.
Publicado: (2021)

Chronic Activation of Corticotropin-Releasing Factor Type 2 Receptors Reveals a Key Role for 5-HT1A Receptor Responsiveness in Mediating Behavioral and Serotonergic Responses to Stressful Challenge
por: Neufeld-Cohen, Adi, et al.
Publicado: (2012)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

The RECQL helicase prevents replication fork collapse during replication stress
por: Benedict, Bente, et al.
Publicado: (2020)

High‐throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells
por: Tuijnenburg, Paul, et al.
Publicado: (2019)

Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in KRAS Mutant Non-Small Cell Lung Cancer Cell Lines
por: da Silva-Oliveira, Renato José, et al.
Publicado: (2022)

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors
por: Gupta, Jalaj, et al.
Publicado: (2015)

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2018)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
por: Šuštić, Tonći, et al.
Publicado: (2021)

Pharmacologic inhibition of PI3K p110δ in mutant Shp2E76K-expressing mice
por: Deng, Lisa, et al.
Publicado: (2017)

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
por: Curtis, Nicola J., et al.
Publicado: (2017)

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
por: Serresi, Michela, et al.
Publicado: (2018)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2015)

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
por: Sestak, Vit, et al.
Publicado: (2015)

PRDX2 and PRDX4 are negative regulators of hypoxia-inducible factors under conditions of prolonged hypoxia
por: Luo, Weibo, et al.
Publicado: (2016)

Role of aberrant PI3K pathway activation in gallbladder tumorigenesis
por: Lunardi, Andrea, et al.
Publicado: (2014)

A negative feedback regulatory loop between miR-138 and TP53 is mediated by USP10
por: Luo, Zhenghua, et al.
Publicado: (2019)

The impact of the MYB-NFIB fusion proto-oncogene in vivo
por: Mikse, Oliver R., et al.
Publicado: (2016)

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer
por: Bria, Emilio, et al.
Publicado: (2014)

SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker
por: Kolukula, Vamsi K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f9jvjp6f46lsqijgjo1d1l7v8g